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Abstract
Background. The presence of silent brain infarction (SBI)
increases the risk of symptomatic stroke and dementia. The
associationbetweenSBIandchronickidneydisease(CKD)
has not been clarified. Moreover, little is known about what
factors are related to SBI in CKD patients and whether
the prevalence of SBI differs in CKD stage or cause of
CKD.
Methods. This is a cross-sectional study. A total of
375 subjects—335 with CKD and 40 with essential
hypertension—wereincluded.Allsubjectsunderwentmag-
netic resonance imaging (MRI) of the brain to detect SBI.
Glomerularfiltrationrate(GFR)wasestimatedusingMod-
ification of Diet in Renal Disease equation, and cardiovas-
cular risk factors were examined.
Results. The prevalence of SBI was 56.5% in all sub-
jects. Among causes of CKD, hypertensive nephrosclerosis
had a strong association with SBI. According to the es-
timated GFR (eGFR) stage, the more severe the stage of
eGFR, the higher the prevalence of SBI (age-adjusted odds
ratio [95% confidence interval] for eGFR 30–59, 15–29
and <15 versus ≥60 mL/min/1.73 m2: 1.34 [0.68–1.99],
1.94 [1.30–2.57] and 2.51 [1.91–3.10]). In multivariate lo-
gistic analysis, eGFR was related to SBI independently,
in addition to age and blood pressure (P = 0.025).
However, other traditional and non-traditional risk factors
were not.
Conclusion.Therewasanindependentassociationbetween
eGFR and SBI. CKD patients should receive active detec-
tion of SBI and more intensive preventive management,
especially for hypertension, should be needed in CKD pa-
tients to prevent SBI.
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Introduction
Silent brain infarction (SBI) is defined as a cerebral infarc-
tion that is evident on brain imaging but is not associated
with a clinical symptom [1]. In most cases, SBI is found
as a lacunar infarction that is a small, deep cerebral in-
farction caused by occlusion of small penetrating cerebral
arteries [2]. Therefore, SBI is categorized as small vessel
disease and thus differs from other cardiovascular disease,
suchasischaemicheartdisease(IHD),aorticdissectionand
atherothrombotic cerebral infarction, because they are cat-
egorized as large vessel disease. SBI is seen on magnetic
resonance imaging (MRI) both in patients with an overt
stroke and in healthy elderly persons. It has been reported
that the prevalence of SBI in the general population was
from 8% to 28%, with the differences mainly explained
by age [1]. The presence of SBI can predict clinical overt
stroke [3,4] or reduced cognitive function [5,6]. It has been
demonstrated that risk factors for SBI are not necessarily
the same as those for clinical stroke [1,7], and several stud-
ies have consistently found that advanced age [3,4,8,9] and
hypertension [3,8,9] are the most common risk factors for
SBI.
Chronic kidney disease (CKD) has been shown to be an
independent risk factor for cardiovascular disease [10–12],
and cardiovascular disease is a leading cause of morbidity
and mortality in CKD patients [13,14]. Similarly, several
reports have indicated that CKD is associated with a high
prevalence of stroke [10,11,15–19]. However, the associa-
tion between CKD and SBI has not been clarified, and little
is known about what factors are related to SBI in CKD
patients.
The purpose of this study is to determine the prevalence
andriskfactorsofSBIinCKDpatientswithawiderangeof
glomerularfiltrationrate(GFR)andtoexaminethestrength
C   The Author [2008].
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version
of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed
as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or
as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org202 M. Kobayashi et al.
of association between the prevalence of SBI and GFR
stages.
Subjects and methods
Subjects
To determine the implications of CKD for the preva-
lence of SBI, we examined 335 elderly patients with CKD
(stages 1–5) and 40 elderly patients with essential hyper-
tension (EHT). A total of 375 subjects were enrolled, and
all subjects attended the Department of Internal Medicine
of Yokohama City University Medical Center, Japan, be-
tween August 2004 and October 2007. Exclusion criteria
were subjects having a past history of stroke or transient is-
chaemicattacks(TIA),receivingrenalreplacementtherapy
(RRT)orhavingapasthistoryofRRTandnotinagreement
with our study.
GFR was estimated using the Modification of Diet in
Renal Disease (MDRD) equation, as follows [20]:
eGFR(mL/min/1.73m2) = 175 × SCr(mg/dL)−1.154
×age(years)−0.203 × 0.742(if female).
CKD was defined as either kidney damage or eGFR
<60 mL/min/1.73 m2 for 3 or more months [21]. Kid-
ney damage was defined as pathologic abnormalities or
markers of damage, including abnormalities in blood or
urine tests or imaging studies [21]. CKD staging was
based on eGFR. We classified eGFR into the following
ranges:≥60mL/min/1.73m2 (stage1or2),30–59mL/min/
1.73 m2 (stage 3), 15–29 mL/min/1.73 m2 (stage 4) and
<15 mL/min/1.73 m2 (stage 5), according to the Kidney
Disease Outcomes Quality Initiative stages [21]. All sub-
jects with EHT had no kidney damage as described above,
and their eGFR were not <60 mL/min/1.73 m2.
The ethical committee of Yokohama City University
Medical Center approved the protocol, and written in-
formed consent was obtained from all subjects.
Silent brain infarction
All subjects underwent MRI of the brain. We performed
axial T1-, T2- and proton-density-weighted scans on 1.5-
T MRI scanners (Siemens AVANTO, Germany). The slice
thickness was 6 mm with an interslice gap of 1.5 mm. We
defined SBI as a focal area ≥3 mm and <20 mm in di-
ameter in both T1- and T2-weighted scans that was visible
as a low-intensity area on the T1-weighted image and as
a high-intensity area on the T2-weighted image. Proton-
density scans were used to distinguish infarctions from di-
lated perivascular spaces. Two trained physicians who had
not been notified of any clinical information assessed the
MR images independently. Their evaluation had an inter-
reader intraclass correlation of 0.99.
We determined history of stroke and TIA by self-
reporting, and by checking the medical records of all sub-
jects, independent of their MRI outcome. We defined SBI
as evidence on MRI of one or more infarctions, without a
history of a stroke or TIA.
Risk factors
At the baseline examination, each subject completed a self-
administered questionnaire covering their medical history,
drugs received at least over the last year, smoking habit
and alcohol intake. Trained interviewers at the screen-
ing checked the questionnaire, and the study physicians
performed a physical examination of each subject and
rechecked their medical history to improve the accuracy
of the information.
Smoking habit was classified as current, past and never.
With smokers, the Brinkmann index (cigarettes × year)
was calculated. Alcohol intake was converted to grams of
ethanol per day. We checked history of IHD, diabetes mel-
litus and hypertension. IHD was defined as either angina,
history of myocardial infarction, coronary artery bypass
surgeryorpercutaneoustransluminalcoronaryangioplasty.
Diabetes mellitus was defined according to the criteria rec-
ommended by the American Diabetes Association [22],
in addition to a medical history of diabetes mellitus. Hy-
pertension was diagnosed when blood pressure (BP) was
≥140/90 mmHg or patients were receiving antihyperten-
sive treatments. BP was measured at least three times, after
5minofrest,bytrainedobserversusingastandardmercury
sphygmomanometer with the subject in the sitting position.
The mean data were used for analysis.
Blood samples were collected after an overnight fast for
the determination of serum creatinine, haemoglobin, fib-
rinogen, total protein, albumin, triglycerides, total choles-
terol (TC), low-density lipoprotein (LDL), high-density
lipoprotein (HDL), calcium concentration, phosphate con-
centration,parathyroidhormone(PTH)andhigh-sensitivity
C-reactive protein (hs-CRP). These specimens were as-
sayed within 1 h. Serum creatinine concentration was mea-
sured by an enzymatic method. Serum calcium concentra-
tion was corrected for the serum albumin concentration,
and the calcium–phosphate product was calculated. PTH
measurements were based on an intact molecule assay. Pro-
teinuria (g/day) was checked by collecting 24-h urine in
CKD patients.
Statistical analysis
The SAS software package was used to perform all statis-
tical analyses. All data are expressed as mean ± SD. eGFR
wasclassifiedintofourcategories,andbaselinecharacteris-
ticswerecomparedamongeGFRcategories.Themeanval-
uesofselectedconditionswereexaminedusingchi-squared
statistics for categorical variables and one-way ANOVA of
variance for continuous variables. Differences in the preva-
lence of SBI between eGFR categories, causes of CKD
and nature of antihypertensive drugs were tested by logistic
regression analysis. Age- or multivariable-adjusted odds
ratios and 95% confidence intervals were also estimated
by the use of multiple logistic regression analysis. Differ-
ences between the two groups, patients with SBI and those
without, were analysed by means of unpaired Student’s t-
test. Chi-squared test was used to calculate the P-value forRelationship between SBI and CKD 203
Table 1. Demographic and clinical characteristics by the eGFR category
Estimated GFR (mL/min/1.73 m2)
Overall ≥60 30–59 15–29 <15 P-value
Number of patients 375 101 76 84 114
Number of patients with SBI 212 38 43 53 78
Men (%) 60.3 45.5 72.4 66.7 60.5 <0.001
Age (year) 63.5 ± 14.0 56.0 ± 13.7 67.4 ± 12.5 65.7 ± 12.8 65.9 ± 13.7 <0.001
Body mass index (kg/m2) 24.1 ± 4.1 24.7 ± 4.7 24.1 ± 4.3 24.1 ± 3.9 23.7 ± 3.6 NS
Hypertension (%) 87.7 79.2 85.5 89.3 95.6 <0.01
Diabetes mellitus (%) 37.1 16.8 27.6 53.6 49.1 <0.001
History of ischaemic heart disease (%) 17.1 3.0 21.1 23.8 21.1 <0.001
Smoking habit
Current (%) 22.7 24.2 29.7 25.0 16.5 NS
Past (%) 33.1 25.3 29.7 39.3 39.1 NS
Never (%) 44.2 50.5 40.6 35.7 44.4 NS
Brinkmann index (cigarettes × year) 457.0 ± 648.3 299.6 ± 463.3 515.2 ± 594.8 556.9 ± 678.6 477.3 ± 766.9 0.04
Alcohol intake
Ethanol 0 g/day (%) 47.0 42.1 38.7 51.8 53.1 NS
Ethanol 0–20 g/day (%) 19.9 32.6 18.7 15.7 13.4 0.01
Ethanol >20 g/day (%) 33.1 25.3 42.6 32.5 33.5 NS
Systolic blood pressure (mmHg) 144.3 ± 26.9 138.3 ± 22.1 141.9 ± 24.3 144.4 ± 29.9 151.1 ± 28.8 <0.01
Diastolic blood pressure (mmHg) 77.3 ± 18.4 80.8 ± 16.3 77.5 ± 17.4 76.4 ± 19.7 74.9 ± 19.6 NS
Total cholesterol (mg/dL) 196.9 ± 55.3 213.6 ± 60.1 197.5 ± 51.8 195.9 ± 51.5 182.8 ± 52.5 <0.001
Triglycerides (mg/dL) 154.2 ± 94.1 151.5 ± 85.5 163.4 ± 102.5 171.1 ± 99.8 138.0 ± 89.3 NS
High-density lipoprotein cholesterol (mg/dL) 50.9 ± 18.2 59.8 ± 21.5 52.3 ± 17.4 46.7 ± 15.1 46.2 ± 15.2 <0.001
Low-density lipoprotein cholesterol (mg/dL) 115.5 ± 45.5 129.1 ± 47.3 113.7 ± 43.9 115.0 ± 44.7 106.3 ± 40.5 <0.01
Estimated GFR (mL/min/1.73 m2) 40.1 ± 34.6 90.4 ± 19.6 41.4 ± 8.4 21.6 ± 4.5 8.2 ± 2.9 <0.001
Proteinuria (g/day) 1.8 ± 2.8 0.9 ± 2.5 1.6 ± 3.4 2.1 ± 2.5 2.4 ± 2.8 <0.01
Haemoglobin (g/dL) 11.2 ± 2.6 13.7 ± 1.7 12.0 ± 2.0 10.5 ± 1.8 8.9 ± 1.6 <0.001
Fibrinogen (mg/dL) 446.2 ± 132.9 400.8 ± 150.3 441.5 ± 127.8 441.7 ± 114.9 473.6 ± 132.5 0.01
Albumin (g/dL) 3.7 ± 0.7 4.0 ± 0.9 3.8 ± 0.6 3.5 ± 0.7 3.5 ± 0.6 <0.001
Hs-CRP (mg/dL) 0.243 ± 0.392 0.138 ± 0.142 0.238 ± 0.270 0.254 ± 0.388 0.330 ± 0.560 <0.01
Calcium (mg/dL) 9.2 ± 0.8 9.6 ± 0.5 9.4 ± 0.5 9.3 ± 0.8 8.8 ± 1.0 <0.001
Phosphate (mg/dL) 4.2 ± 1.4 3.4 ± 0.6 3.4 ± 0.6 3.9 ± 0.9 5.5 ± 1.6 <0.001
Calcium × phosphate product (mg2/dL2) 38.3 ± 11.9 33.1 ± 6.2 31.9 ± 5.8 36.2 ± 7.8 48.4 ± 14.2 <0.001
Intact PTH (pg/mL) 172.7 ± 231.1 49.9 ± 30.2 77.5 ± 64.0 123.3 ± 63.3 275.8 ± 316.4 <0.001
Values are expressed as mean ± SD or percentage.
GFR, glomerular filtration rate; PTH, parathyroid hormone.
categorical variables. Variables associated with SBI in uni-
variable analysis were entered into a multivariable model
using logistic regression methods to determine the power
of each variable for predicting SBI. We performed multi-
linear regression analysis of factors related to the number
of SBI. P < 0.05 was considered statistically significant in
all analyses.
Results
Clinicalanddemographic detailsofourstudyarepresented
in Table 1.
Of 375 patients, 226 were men and 149 were women.
The mean age was 63.5 ± 14.0 years (range, 27–89 years),
and the mean eGFR was 40.1 ± 34.6 mL/min/1.73 m2.S B I
was present in 212 (56.5%) patients.
Of 335 CKD patients, 274 were diagnosed with CKD
because of their eGFR, and 61 were diagnosed with CKD
because of their kidney damage despite that their eGFR
were ≥60 mL/min/1.73 m2. Causes of CKD were chronic
glomerulonephritis (n = 89; 26.6%), diabetes mellitus
(n = 114; 34.0%), hypertensive nephrosclerosis (n = 81;
24.2%), polycystic kidney disease (n = 14; 4.2%) and oth-
ers (n = 37; 11.0%). And 46.1% of patients with chronic
gromerulonephritis, 57.9% of patients with diabetes mel-
litus, 74.1% of patients with hypertensive nephrosclero-
sis and 57.1% of patients with polycystic kidney disease
had SBI. The prevalence of SBI in patients with hyper-
tensive nephrosclerosis was twofold higher than that with
non-hypertensive nephrosclerosis CKD patients after ad-
justment for age and eGFR (odds ratio [95% confidence
interval]: 2.14 [1.54–2.74]).
According to the eGFR category, 38 of 101 patients
(37.6%) with eGFR ≥60 mL/min/1.73 m2,4 3o f7 6p a -
tients (56.6%) with eGFR 30–59 mL/min/1.73 m2,5 3o f8 4
patients(63.1%)witheGFR15–29mL/min/1.73m2 and78
of 114 patients (68.4%) with eGFR <15 mL/min/1.73 m2
hadSBI.Age-andmultivariable-adjustedoddsratiosbythe
eGFR category for the prevalence of SBI were estimated
(Table 2). This showed that the more severe the category of
eGFR,thehighertheprevalenceofSBI.Theserelationships
remainedsubstantiallyunchangedevenafteradjustmentfor
other traditional cardiovascular risk factors, such as hyper-
tension, diabetes mellitus and hyperlipidaemia.
Figure 1 shows the odds ratio of the prevalence of SBI
categorizedbyeGFRandsystolicBP(sBP).Inbothpatients
with sBP ≥140 mmHg and those with sBP <140 mmHg,204 M. Kobayashi et al.
Table 2. Association between the eGFR category and the prevalence of
SBI
Odds ratio (95% confidence interval)
Estimated GFR
(ml/min/1.73 m2) Age-adjusted Multivariable-adjusteda
≥60 1.00 1.00
30–59 1.34 (0.68–1.99) 1.41 (0.74–2.09)
15–29 1.94 (1.30–2.57) 2.27 (1.58–2.95)
<15 2.51 (1.91–3.10) 2.62 (1.97–3.27)
aThe analysis was adjusted for age, the presence of hypertension, diabetes
mellitus and hyperlipidaemia.
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Fig.1. Age-standardizedoddsratioofSBI,categorizedbyeGFRandsys-
tolicBP(sBP)(eGFR≥60,15–59,<15mL/min/1.73m2)and(sBP≥140,
<140 mmHg). Numbers of patients in each column were 58, 77 and 37
(left to right) for the near side (sBP <140 mmHg) and 43, 83 and 77 (left
toright)forthefarside(sBP≥140mmHg).TheoddsratioofSBIforeach
columnversus≥60mL/min/1.73m2 andsBP<140mmHgwas1.00,1.63
and 2.86 (left to right) for the near side (sBP <140 mmHg) and 2.17, 3.17
and 3.90 (left to right) for the far side (sBP ≥140 mmHg).
the prevalence of SBI increased as eGFR decreased. Pa-
tients with sBP <140 mmHg had a lower prevalence of
SBI compared to those with sBP ≥140 mmHg in all eGFR
categories. However, the influence of sBP became smaller
as the eGFR category worsened.
Next, we analysed the patients by dividing them into two
groups: those with SBI and those without SBI. Table 3
shows the baseline characteristics of the patients in these
two groups. According to Table 3, age, prevalence of hy-
pertension, history of IHD, Brinkmann index and sBP were
higher whereas TC, HDL, LDL, eGFR and haemoglobin
were lower in patients with SBI. Other traditional risk fac-
tors for cardiovascular disease, such as male sex, alcohol
intake and diabetes mellitus, were not different in the two
groups. In this study, we also investigated the relationships
between SBI and non-traditional risk factors, such as pro-
teinuria, anaemia, fibrinogen, albumin, hs-CRP and min-
eral metabolism of calcium and phosphate. Among these
factors, only haemoglobin was different in the two groups;
however,thedifferencewasnotsignificantafteradjustment
foreGFR.Inrelationtomineralmetabolismofcalciumand
phosphate, we also investigated the association between
SBI and the use of vitamin D (alfacalcidol and calcitriol)
by comparing the prevalence ratio of these drugs between
the two groups, but found no difference. Multivariable lo-
gistic analysis of factors that had a statistically significant
relationship with SBI by univariable analysis revealed that
eGFR had a graded association with the prevalence of SBI,
in addition to age and sBP (Table 4).
Furthermore, we analysed the association between SBI
and antihypertensive drugs. For each drug, we found no
association with SBI. However, we found the following
association by focusing on angiotensin (AT) II formation
of each drug. We divided the patients receiving antihyper-
tensive treatments into two groups: those receiving only
drugs potentially increasing AT II (AT II type I recep-
tor antagonists, diuretics and long-acting dihydropyridine
calcium antagonists) and those receiving both drugs po-
tentially increasing AT II and drugs potentially decreasing
AT II (AT-converting enzyme inhibitors, beta-blockers and
long-acting non-dihydropyridine calcium antagonists). The
prevalence of SBI in the latter was statistically higher than
that in the former after adjustment for age, sBP and eGFR
(odds ratio [95% confidence interval]: 1.75 [1.21–2.29]).
To enhance the causal association of eGFR with SBI,
analysis of the relationship between the number of SBI
and eGFR was performed (Table 5). There was a signifi-
cant negative correlation between the number of SBI and
eGFR.
Discussion
Ourstudydemonstratedthestrengthofassociationbetween
SBI and eGFR.
There has been rapidly growing interest in the relation-
ship between CKD and cardiovascular disease. However,
little information has been available on the relationship be-
tween kidney and brain compared to kidney and heart. In
cerebral disease, SBI is asymptomatic, but is important as a
predictorofstrokeanddementia.Topreventthesedisorders
and keep a good quality of life, the control of risk factors
for SBI is necessary. In this regard, our report, showing the
association between CKD and SBI, would be meaningful.
There are two types of cerebral small vessel disease:
SBI and white matter lesions (WML). Recently, it has
been shown that eGFR was associated with WML [23,24].
However, the association between SBI and eGFR has
not been clarified. Ikram et al. showed that there was
no significant association between SBI and eGFR, de-
spite showing a significant association between WML
and eGFR [23]. However, the prevalence in severe stage
CKD patients has not been sufficiently examined, and
uraemia-related factors were not fully analysed because
the study population had relatively good renal function
(mean eGFR 54.8 mL/min/1.73 m2). On the other side,
in patients with more severe CKD, Kobayashi et al.s h o w e d
that the prevalence of SBI in patients with creatinine clear-
ance (CCr) <40 mL/min/1.73 m2 was significantly higher
than that in those with CCr ≥40 mL/min/1.73 m2 (n = 51)
[25]. However, their results were not adjusted for age and
BP. Therefore, it remains unclear whether the high preva-
lence of SBI in CKD patients depends on age and/or BP,
which are common strong risk factors for SBI and increaseRelationship between SBI and CKD 205
Table 3. Characteristics of patients with and without SBI
With SBI Without SBI P-value
Number of patients 212 163
Men (%) 62.7 57.0 NS
Age (year) 67.7 ± 11.1 58.1 ± 15.5 <0.0001
Body mass index (kg/m2) 23.9 ± 3.6 24.4 ± 4.6 NS
Hypertension (%) 94.8 78.5 <0.0001
Diabetes mellitus (%) 37.7 36.2 NS
History of ischaemic heart disease (%) 21.2 11.7 0.027
Smoking habit
Current (%) 24.8 20.0 NS
Past (%) 33.0 33.1 NS
Never (%) 42.2 46.9 NS
Brinkmann index (cigarettes × year) 532.6 ± 714.0 359.1 ± 537.5 0.011
Alcohol intake
Ethanol 0 g/day (%) 46.8 46.9 NS
Ethanol 0–20 g/day (%) 17.1 23.7 NS
Ethanol >20 g/day (%) 36.1 29.4 NS
Systolic blood pressure (mmHg) 148.4 ± 27.8 138.9 ± 24.9 <0.001
Diastolic blood pressure (mmHg) 78.2 ± 20.1 76.2 ± 16.1 NS
Total cholesterol (mg/dL) 190.6 ± 52.1 205.2 ± 58.3 0.012
Triglycerides (mg/dL) 157.7 ± 99.5 149.6 ± 86.5 NS
High-density lipoprotein cholesterol (mg/dL) 48.5 ± 16.0 54.2 ± 20.5 <0.01
Low-density lipoprotein cholesterol (mg/dL) 110.4 ± 41.7 122.4 ± 47.4 0.017
Estimated GFR (mL/min/1.73 m2) 32.6 ± 30.5 49.7 ± 37.2 <0.0001
Proteinuria (g/day) 1.5 ± 2.2 2.1 ± 3.5 NS
Haemoglobin (g/dL) 10.8 ± 2.4 11.7 ± 2.7 <0.001
Fibrinogen (mg/dL) 443.2 ± 126.4 451.2 ± 143.2 NS
Albumin (g/dL) 3.7 ± 0.7 3.7 ± 0.8 NS
Hs-CRP (mg/dL) 0.253 ± 0.387 0.232 ± 0.399 NS
Calcium (mg/dL) 9.2 ± 0.8 9.3 ± 0.8 NS
Phosphate (mg/dL) 4.2 ± 1.3 4.1 ± 1.5 NS
Calcium × phosphate product (mg2/dL2) 38.6 ± 11.5 37.3 ± 12.4 NS
Intact PTH (pg/mL) 161.8 ± 154.0 188.8 ± 312.3 NS
Values are expressed as mean ± SD or percentage.
GFR, glomerular filtration rate; PTH, parathyroid hormone.
Table 4. Multivariable logistic regression analysis for the prevalence
of SBI
95% confidence
Odds ratio interval P-value
Estimated GFR
(mL/min/1.73 m2)
0.989 0.979–0.998 0.025
Age (year) 1.054 1.034–1.074 <0.0001
Systolic blood pressure
(mmHg)
1.016 1.006–1.026 <0.001
History of ischaemic
heart disease
0.949 0.300–1.598 NS
Brinkmann index
(cigarettes × year)
1.000 0.804–1.196 NS
Haemoglobin (g/dL) 1.083 0.952–1.214 NS
Total cholesterol (mg/dL) 0.997 0.993–1.001 NS
Table 5. Multilinear regression analysis of factors related to number
of SBI
Standard
regression
coefficient tP -value
Estimated GFR (mL/min/1.73 m2) −0.110 −2.118 0.035
Age (year) 0.310 6.073 <0.0001
Systolic blood pressure (mmHg) 0.098 1.981 0.048
as eGFR declines, or whether other uraemia-related factors
play a role in SBI in CKD patients. In addition, their sam-
ple was too small to reach a conclusion on the relationship
between CKD and SBI, and patients with diabetes mellitus,
which is a major cause of CKD, were excluded from their
study.
In the present study, we confirmed that BP and age
were related to SBI in CKD patients, similar to the gen-
eral population. Moreover, we revealed that eGFR was also
associated with SBI independent of age and BP. In addi-
tion, we analysed and compared all-cause CKD patients to
show the prevalence of SBI in each group of CKD patients
and revealed that patients with hypertensive nephroscle-
rosis had a higher prevalence of SBI. It has been clarified
thattheprevalenceofcardiacdiseaseincreasesastheeGFR
stageprogresses[10–12].Weshowedthatthisassociationis
also applied to SBI. These findings may indicate that there
is a cerebro-renal association, similar to the cardio-renal
association.
Yamamoto et al. showed that patients with multiple lacu-
nar infarctions had a higher risk for cardiovascular disease
than patients with a single lacunar infarction [26]. Another
group showed that the number of lacunae was related to the
degree of brain atrophy [27]. Therefore, we also performed
analysis of the relationship between the number of SBI and
eGFR. The results revealed that a decline of eGFR was206 M. Kobayashi et al.
associated with not only the prevalence of SBI but also the
number of SBI independently.
Furthermore,weinvestigatedthecauseofthehighpreva-
lence of SBI in CKD patients. Reduced kidney func-
tion is associated with increased levels of inflamma-
tory factors [28,29], enhanced coagulability [29], anaemia
[30] and calcium–phosphate abnormality. Moreover, CKD
patients often have proteinuria. Thus, we investigated
these non-traditional factors: hs-CRP, albumin, fibrinogen,
haemoglobin, mineral metabolism of calcium and phos-
phate and proteinuria. However, we could not find any in-
fluence of these factors on the prevalence of SBI. These
results suggest that these factors do not play a major role
in SBI alone and other non-traditional factors or the com-
bination of multiple non-traditional risk factors affect the
prevalence of SBI in CKD patients. However, more studies
are needed to clarify why eGFR associates with SBI inde-
pendently. For traditional factors, it has been cleared that
smoking, dyslipidaemia and diabetes mellitus are risk fac-
torsforstrokeinadditiontoadvancedageandhypertension,
and CKD patients often share these risk factors. Although
no relationship was seen between these factors and SBI in
our study, the strict control of multiple cardiovascular risk
factors including these factors may be necessary in CKD
patients to prevent cerebral dysfunction.
Meanwhile, hypertension and sBP associated with SBI
very strongly in CKD patients. We investigated the preva-
lence of SBI, categorized by eGFR and sBP. The results
revealed that not only the prevalence of SBI increased as
the eGFR category worsened, but also the prevalence of
SBI was markedly lower in patients whose hypertension
was appropriately treated. In addition, patients with hyper-
tensive nephrosclerosis had higher prevalence of SBI than
those with other causes of CKD. This indicates that there is
alinkbetweenvasculardiseaseofthekidneyandbrain,and
hypertension is important as a cause of the high prevalence
of SBI in CKD patients. Blood vessels in the kidney and
brain were reported to be highly susceptible to fluctuations
in BP and flow because the vascular beds of both the kid-
ney and brain have very low resistance and are passively
perfused at high flow throughout systole and diastole [31].
Interestingly, this mechanism is present only in the kidney
and brain, and it causes small-vessel injury in these organs.
Therefore, BP control may be especially important to pre-
vent small-vessel disease of the kidney and brain in CKD
patients, and our results support this report.
We also considered whether the prevalence of SBI was
different in the nature of antihypertensive treatments. Ex-
perimental data in rodents have documented that activation
of AT2 receptor of AT II may exert anti-ischaemic mecha-
nisms in the brain [32–35]. In addition, the meta-analysis
of randomized clinical trials have hypothesized that drugs
increasing AT II are more stroke protective than drugs de-
creasing AT II [36]. In our study, most patients were treated
with combined antihypertensive drugs. Furthermore, most
of them received at least one of the drugs potentially in-
creasing AT II. Thus, we analysed the association between
SBI and AT II formation by dividing patients receiving an-
tihypertensive treatments into two groups: those receiving
only drugs potentially increasing AT II and those receiv-
ing both drugs potentially increasing AT II and drugs po-
tentially decreasing AT II. By using multivariable logistic
regression analysis, we showed that the prevalence of SBI
in the latter was statistically higher than that in the former
even after adjustment for factors that were associated with
SBI independently in our study. Our results may support
the hypothesis that drugs increasing AT II have a protective
effect on brain ischaemia.
However, our study has several limitations. Firstly, it
was cross-sectional, and therefore, a prospective study con-
cerning the development of SBI may warrant the results.
Secondly, we chose EHT patients as controls to consider
whether eGFR associated with SBI independently, because
most CKD patients had hypertension, which was a strong
risk factor for SBI. Thus, we did not adopt the age-matched
healthy subjects in the present study. However, it is an im-
portant and interesting point to gather and compare CKD
patients to the age-matched healthy volunteer. We would
like to reveal this problem in the future study. Finally, GFR
was estimated by the MDRD equation. The equation we
used is widely accepted. However, it may not be accurate
across racial groups because of difference among races in
creatinine generation. In order to compensate the MDRD
equation, we re-analysed our data using the MDRD equa-
tion modified for Japanese [37] and the Cockcroft–Gault
equation for CCr [38] and confirmed that the results were
the same as those using the MDRD equation (data not
shown). This reproducibility would guarantee the results
of our study.
Despite these limitations, we described the graded asso-
ciationbetweeneGFRandSBIinpatientswithawiderange
of eGFR and reported the prevalence of SBI according to
eGFR stage and cause of CKD. Moreover, we showed the
importance of CKD as a predictor not only of SBI but also
of the number of SBI.
In conclusion, CKD associates with SBI independently.
Furthermore, the prevalence of SBI and the number of SBI
increased markedly as eGFR decreased. Our findings sug-
gest that CKD patients should be considered as a high-
risk population for SBI, which is a risk for stroke and de-
mentia, and be recommended for more intensive preventive
management, including active detection of SBI and strict
treatment of multiple cardiovascular risk factors, especially
hypertension.
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